(Total Views: 897)
Posted On: 02/04/2020 11:50:26 AM
Post# of 155002
Re: chessmaster #16840
My favorite part of the article, although there were many...
"After the bulk of this article was written, an even bigger risk developed for Gilead shareholders. In mid January, CytoDyn filed for Breakthrough Therapy Designation (BTD) in metastatic breast cancer, but on Friday the company requested an emergency meeting with the FDA, and based on the CEO's video, they are planning on requesting immediate approval of leronlimab with a follow on phase 4 trial. Should the FDA grant this request, there could be a violent reaction to the news of leronlimab approval as investors in Gilead realize that once a drug is approved in one indication, the concern over safety diminishes as the attention turns to efficacy. "
And we know our efficacy puts Gilead to shame! Over 90% @ 700mg... 95% at 525mg...
"After the bulk of this article was written, an even bigger risk developed for Gilead shareholders. In mid January, CytoDyn filed for Breakthrough Therapy Designation (BTD) in metastatic breast cancer, but on Friday the company requested an emergency meeting with the FDA, and based on the CEO's video, they are planning on requesting immediate approval of leronlimab with a follow on phase 4 trial. Should the FDA grant this request, there could be a violent reaction to the news of leronlimab approval as investors in Gilead realize that once a drug is approved in one indication, the concern over safety diminishes as the attention turns to efficacy. "
And we know our efficacy puts Gilead to shame! Over 90% @ 700mg... 95% at 525mg...
(2)
(0)
